Abstract
Metformin is a biguanide derivative which is widely prescribed as an oral drug for diabetes mellitus type 2. This old molecule has recently received a new attention because of its therapeutic properties in oncology, that seem to be independent of its action on glycemia homeostasis. The reappraisal of its pharmacological effects was supported by delineation of signaling pathways and more recently clinical trials. Numerous epidemiological studies showed that diabetics have an increased risk of several types of cancer and cancer mortality. Complex relationship between cancer and type 2 diabetes is going to be unraveled and recent observations revealed a significant action of metformin, but not other anti-diabetic agents, on cancer cells. As metformin may act as an anticancer drug through inhibition of mTOR, it might have greater benefice than suggested by insulin lowering alone. This review summarizes major publications on the link between cancer and metformin underscoring new implications of this chemical drug in oncology field. New perspectives about utilization of this molecule in clinical oncological routine, are described, particularly for patients without disturbance of glucose homeostasis. As the epithelial mesenchymal transition (EMT) seems implicated into invasive process and metastasis in cancer, and as metformin is able to inhibit EMT pathways, it is important to highlight cellular mechanisms of metformin.
Keywords: AKT, AMPK, Cancer, Clinical trials, Dedifferentiated circulating tumor cells, Diabetes, EMT, Epidemiology, Insulin, Metformin, mTOR, Neoadjuvant therapy, S6KB, Stemness
Anti-Cancer Agents in Medicinal Chemistry
Title:Metformin: A Rising Star to Fight the Epithelial Mesenchymal Transition in Oncology
Volume: 13 Issue: 2
Author(s): Guislaine Barriere, Michel Tartary and Michel Rigaud
Affiliation:
Keywords: AKT, AMPK, Cancer, Clinical trials, Dedifferentiated circulating tumor cells, Diabetes, EMT, Epidemiology, Insulin, Metformin, mTOR, Neoadjuvant therapy, S6KB, Stemness
Abstract: Metformin is a biguanide derivative which is widely prescribed as an oral drug for diabetes mellitus type 2. This old molecule has recently received a new attention because of its therapeutic properties in oncology, that seem to be independent of its action on glycemia homeostasis. The reappraisal of its pharmacological effects was supported by delineation of signaling pathways and more recently clinical trials. Numerous epidemiological studies showed that diabetics have an increased risk of several types of cancer and cancer mortality. Complex relationship between cancer and type 2 diabetes is going to be unraveled and recent observations revealed a significant action of metformin, but not other anti-diabetic agents, on cancer cells. As metformin may act as an anticancer drug through inhibition of mTOR, it might have greater benefice than suggested by insulin lowering alone. This review summarizes major publications on the link between cancer and metformin underscoring new implications of this chemical drug in oncology field. New perspectives about utilization of this molecule in clinical oncological routine, are described, particularly for patients without disturbance of glucose homeostasis. As the epithelial mesenchymal transition (EMT) seems implicated into invasive process and metastasis in cancer, and as metformin is able to inhibit EMT pathways, it is important to highlight cellular mechanisms of metformin.
Export Options
About this article
Cite this article as:
Barriere Guislaine, Tartary Michel and Rigaud Michel, Metformin: A Rising Star to Fight the Epithelial Mesenchymal Transition in Oncology, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020018
DOI https://dx.doi.org/10.2174/1871520611313020018 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adjunctive Strategies in the Management of Resistant, ‘Undilatable’ Coronary Lesions After Successfully Crossing a CTO with a Guidewire
Current Cardiology Reviews Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Infrequent Infections in COPD
Current Respiratory Medicine Reviews Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design Diabetic Nephropathy: Causes and Managements
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Common Therapeutic Strategies for Diabetic Retinopathy and Glaucoma
Current Drug Therapy Applications of Natural Polymeric Materials in Solid Oral Modified-Release Dosage Forms
Current Pharmaceutical Design Gene Expression Profiles in Human Autoimmune Disease
Current Pharmaceutical Design Insulin Resistance and Polycystic Ovary Syndrome Through Life
Current Pharmaceutical Design Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Current Pharmaceutical Biotechnology The Predictive Value of Vessel-Based Calcium Score in the Detection of Coronary Stenosis
Current Medical Imaging Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Current Pharmaceutical Design Troglitazone Thiol Adduct Formation in Human Liver Microsomes: Enzyme Knietics and Reaction Phenotyping
Drug Metabolism Letters EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets Insights into the Regulation of Renal Hemodynamic Function in Diabetic Mellitus
Current Diabetes Reviews Pharmacological Management of Diabetic Nephropathy
Current Vascular Pharmacology